From the Department of Ophthalmology, Istanbul Medipol University, Faculty of Medicine, Istanbul, Turkey (Keskin Perk, Tanriverdi, Haciagaoglu, Karaca, Kilic); Department of Ophthalmology, St. Franziscus Hospital, Münster, Germany (Taneri).
J Cataract Refract Surg. 2023 Oct 1;49(10):1005-1010. doi: 10.1097/j.jcrs.0000000000001270.
To demonstrate the safety and efficacy of allogenic corneal inlays designed to increase the depth of focus (DoF) in treated eyes.
Medipol University Hospital, Istanbul, Turkey.
Prospective case series.
This study includes 50 eyes of 25 patients with a follow-up of 3 years. Emmetropic patients with presbyopia had implantation of allogenic corneal inlays in the nondominant eye. The uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and uncorrected near visual acuity (UNVA) were evaluated in all eyes. A subjective visual acuity test system (Multifocal Lens Analyzer 3.0 application) was used to analyze the DoF by measuring the defocus curves.
No significant difference between the treated and fellow eyes in UDVA and CDVA was found, whereas UNVA was significantly better in the treated eyes ( P = .20, P = .07, P < .01, respectively). Comparing to the preoperative CDVA, there was a 1-line decrease in CDVA in 6 (%24) patients. The mean defocus curves reveal a DoF of 1.1 diopters (D) for the untreated eye at the logMAR = 0.2 threshold. By contrast, the mean DoF of the treated eye and binocularly was 2.8 D. The areas under the curve were significantly better in the near, intermediate, and total distances in the treated eyes, whereas it was better for the far distances in the untreated eyes. All values were significant ( P = .023 total, P < .01 others).
Allogenic presbyopic inlay implantation may be safe and provided a clinically and statistically significant increase in the DoF leading to good far, intermediate, and near-visual acuity in emmetropic presbyopic patients.
展示用于增加治疗眼焦点深度(DoF)的同种异体角膜嵌体的安全性和有效性。
伊斯坦布尔 Medipol 大学医院,土耳其。
前瞻性病例系列。
本研究纳入了 25 名患者的 50 只眼,随访时间为 3 年。患有远视性老视的正视眼患者在非主导眼植入同种异体角膜嵌体。所有眼均评估未矫正远视力(UDVA)、矫正远视力(CDVA)和未矫正近视力(UNVA)。使用主观视力测试系统(多焦点透镜分析仪 3.0 应用程序)通过测量离焦曲线来分析景深。
在 UDVA 和 CDVA 方面,治疗眼与对侧眼之间无显著差异,而 UNVA 在治疗眼明显更好(P =.20、P =.07、P <.01)。与术前 CDVA 相比,6 名(24%)患者的 CDVA 下降 1 行。平均离焦曲线显示未治疗眼在 logMAR = 0.2 阈值时的 DoF 为 1.1 屈光度(D)。相比之下,治疗眼和双眼的平均 DoF 为 2.8 D。在治疗眼,近、中、总距离的曲线下面积明显更好,而未治疗眼的远距视力更好。所有值均有统计学意义(总 P =.023,其他 P <.01)。
同种异体老视嵌体植入可能是安全的,并提供了临床上和统计学上显著增加的 DoF,使正视性老视患者获得良好的远、中、近视力。